There's already stiff competition in the oral psoriasis category, however, from drugs with different mechanisms of action, including Amgen's PDE4 inhibitor Otezla (apremilast) – already making ...

Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code Q9999 is for "Injection, for subcutaneous use or intravenous use, ustekinumab-aauz (Otulfi), biosimilar per 1.0 mg." ...

Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code Q9999 is for “Injection, for subcutaneous use or intravenous use, ustekinumab-aauz (Otulfi), biosimilar per 1.0 mg.” ...

Fresenius Kabi, an operating company of Fresenius, announced that the Centers for Medicare and Medicaid Services issued a permanent, product-specific billing code for Otulfi (ustekinumab-aauz).

Amgen today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial ...

The company is known for products such as Darzalex, Stelara, and Tremfya. Its MedTech segment offers medical devices across orthopaedics, surgery, and vision care. JNJ ranked eighth on our recent ...

As always, AbbVie did not disappoint me with its financial results for the first quarter of 2025. It beat the analyst consensus estimates by a wide margin, thanks to the strong performance of its ...

The company is known for products such as Darzalex, Stelara, and Tremfya. Its MedTech segment offers medical devices across orthopaedics, surgery, and vision care. JNJ ranked eighth on our recent ...

Medically reviewed by Corinne Savides Happel, MD Allergies don't cause psoriasis, but you may be more likely to have ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

Option Care Health (NASDAQ:OPCH) reported its first-quarter 2025 earnings, showcasing a robust performance with earnings per share (EPS) of $0.40, surpassing the forecasted $0.33. Despite this ...